Viking Therapeutics Launches $400M Dual Offering to Fund Obesity Pipeline
VKTX sits 67% above its 52-week low of $24.78 on elevated volume (4.7× avg).
Summary
Viking Therapeutics is raising $400M through concurrent offerings of $200M in common stock and $200M in convertible senior notes due 2032, each with a 30-day underwriters' option for up to $30M more. The proceeds will fund late-stage development of VK2735 and VK3019, plus R&D and G&A. This follows positive Phase 2 maintenance data for VK2735 reported yesterday and the recent initiation of the Phase 3 Vanquish program. The equity component is dilutive and the convertible notes add potential future dilution, creating near-term overhang on the stock. Pricing terms—interest rate, conversion premium, and discount—will determine the actual dilution and set the trading range. The company had $502M in cash as of Q2 2026, so this raise extends runway significantly for the obesity pipeline.
At the time of this announcement, VKTX was trading at $41.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $24.78 to $43.15. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.